(Q58024613)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577748%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

title

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577748%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

0 references

0 references

1 reference

1 reference

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577748%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Alexander M Menzies

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577748%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Georgina V. Long

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577748%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

9

F Stephen Hodi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577748%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

8

Keith T Flaherty

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577748%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

12

Michael B Atkins

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577748%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

5

Nageatte Ibrahim

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577748%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

7

Anasuya Gunturi

1 reference

9 March 2020

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577748%20AND%20SRC:MED&resulttype=core&format=json

author name string

Allison Ackerman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577748%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Oliver Klein

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577748%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Wei Wang

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577748%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

David F McDermott

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577748%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Donald P Lawrence

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577748%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Ryan J Sullivan

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577748%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

language of work or name

English

0 references

publication date

27 February 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577748%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577748%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

volume

120

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577748%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577748%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

1695-1701

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577748%20AND%20SRC:MED&resulttype=core&format=json

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

9 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28620

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28620

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28620

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28620

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28620

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28620

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28620

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28620

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28620

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28620

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28620

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28620

Management of immune-related adverse events and kinetics of response with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28620

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28620

Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28620

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28620

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28620

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CNCR.28620

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24577748%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference